Fluvirin (Seasonal Influenza Vaccine) Forecast and Market Analysis

Description: Fluvirin (Seasonal Influenza Vaccine) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluvirin (Seasonal Influenza Vaccine) Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Fluvirin is a trivalent, inactivated influenza vaccine designed to immunize recipients against seasonal influenza infections. The vaccine is prepared from influenza virus viruses that are propagated in embryonated chicken eggs. Each viral strain is harvested via centrifugation and inactivated with beta-propiolactone. The viral surface antigens (i.e., hemagglutinin, neuraminidase) are then purified via centrifugation. Fluvirin is administered via intramuscular injection, where the viral antigens elicit an immune response that helps protect the recipient from subsequent influenza infection. Fluvirin is marketed in the US and UK by Novartis.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fluvirin including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fluvirin from 2012 to 2022.
- Sales information covered for the US, and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Fluvirin performance
- Obtain sales forecast for Fluvirin from 2012 to 2022 in the US, and the UK.

Contents:

1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
Disease Management

4.1 Influenza Vaccination Policy

Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

5.3 Product Profile - Fluvirin

5.3.1 Overview

5.3.2 Efficacy

5.3.3 Safety

5.3.4 SWOT Analysis

5.3.5 Forecast

Appendix

6.1 Abbreviations

6.2 Bibliography

6.3 Methodology

6.4 Forecasting Methodology

6.4.1 Vaccine Coverage

6.4.2 Influenza Vaccine Tender System Assumptions

6.4.3 General Pricing Assumptions

6.4.4 Individual Vaccine Assumptions

6.5 Physicians and Specialists Included in this Study

6.6 Primary Research - Prescriber Survey

6.7 About the Authors

6.7.1 Authors

6.7.2 Global Head of Healthcare

6.8 About Us

6.9 Contact Us

6.10 Disclaimer

List of Tables

Table 1: Notable Influenza Pandemics

Table 2: Symptoms of Influenza

Table 3: Influenza Vaccination Recommendation Committees by Country

Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012

Table 5: Leading Influenza Vaccines, 2012

Table 6: Product Profile - Fluvirin

Table 7: Immunogenicity of Agrippal and Fluvirin

Table 8: Fluvirin SWOT Analysis, 2012

Table 9: Global Sales Forecasts ($m) for Fluvirin, 2012-2022

Table 10: Physicians Surveyed, By Country

List of Figures

Figure 1: Influenza Virus Structure

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/2368625/](http://www.researchandmarkets.com/reports/2368625/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Fluvirin (Seasonal Influenza Vaccine) Forecast and Market Analysis
- **Web Address:** [http://www.researchandmarkets.com/reports/2368625/](http://www.researchandmarkets.com/reports/2368625/)
- **Office Code:** SC6JXPH

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 6990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10485</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

- **Title:** [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
- **First Name:** ____________________________  **Last Name:** ____________________________
- **Email Address:** * ____________________________
- **Job Title:** ____________________________
- **Organisation:** ____________________________
- **Address:** ____________________________
- **City:** ____________________________
- **Postal / Zip Code:** ____________________________
- **Country:** ____________________________
- **Phone Number:** ____________________________
- **Fax Number:** ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World